Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Rhea-AI Summary

Hoth Therapeutics (NASDAQ: HOTH) has announced promising preclinical results for its Alzheimer's drug candidate, HT-ALZ. The study, conducted on Alzheimer's model mice, showed significant reductions in astrocyte activity in key brain areas after treatment with HT-ALZ. Notably, the hippocampus showed decreased astrocyte coverage at both 20 mg and 40 mg dose levels compared to the control group, with similar trends observed in the cortex.

These reductions in reactive astrocytes corresponded with improved cognitive performance, suggesting a potential link between HT-ALZ's effect on astrocytic activity and therapeutic benefits. The company is conducting further analysis to determine if the treatment is affecting the size or total number of astrocytes. CEO Robb Knie expressed confidence in these results as Hoth Therapeutics advances HT-ALZ through further studies and clinical trials.

Positive

• Significant reduction in astrocyte activity observed in key brain areas after HT-ALZ treatment
• Decreased astrocyte coverage in hippocampus at 20 mg and 40 mg dose levels
• Improved cognitive performance corresponding with reduced reactive astrocytes
• Potential breakthrough in Alzheimer's treatment indicated by fewer reactive astrocytes in treated groups

Negative

• None.

Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a potential breakthrough in the treatment of Alzheimer's.

NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. In a recent study using Alzheimer's model mice treated with varying doses of HT-ALZ, significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive function.

In the study, astrocyte staining was used to evaluate the impact of different doses of aprepitant on the hippocampus and cortex. The data showed a notable decrease in the percentage of area covered by astrocytes in the hippocampus at both 20 mg and 40 mg dose levels, compared to the vehicle- treated group. A similar trend was observed in the cortex. These reductions in reactive astrocytes corresponded with enhanced cognitive performance in the same dose groups, further indicating that aprepitant's therapeutic benefit may be tied to its impact on astrocytic activity.

Reactive astrocytes, which are typically larger than normal astrocytes, play a role in the progression of neurodegenerative diseases like Alzheimer's. Hoth Therapeutics is currently conducting a secondary analysis to determine whether the size or total number of astrocytes is changing as a result of treatment. Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a potential breakthrough in the treatment of Alzheimer's.

Robb Knie, CEO of Hoth Therapeutics, stated "These preclinical results are a promising step forward in our mission to develop effective therapies for Alzheimer's disease. The reductions in astrocyte activity and the corresponding improvements in cognitive function observed with HT- ALZ give us confidence as we move forward in our development process."

Hoth Therapeutics plans to continue advancing HT-ALZ through further studies and clinical trials, aiming to provide a novel therapeutic option for patients suffering from Alzheimer's disease. For more information on HT-ALZ and Hoth's innovative pipeline, please visit our website.

About Hoth Therapeutics, Inc.

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://hoththerapeutics.com.

Forward-Looking Statement

This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-promising-preclinical-results-for-alzheimers-drug-ht-alz-302249998.html

SOURCE Hoth Therapeutics, Inc.

FAQ

What are the key findings of Hoth Therapeutics' preclinical study for HT-ALZ (HOTH)?

The preclinical study showed significant reductions in astrocyte activity in key brain areas of Alzheimer's model mice treated with HT-ALZ. This reduction corresponded with improved cognitive performance, suggesting a potential therapeutic benefit for Alzheimer's disease.

How does HT-ALZ (HOTH) affect astrocytes in Alzheimer's model mice?

HT-ALZ treatment resulted in a notable decrease in the percentage of area covered by astrocytes in the hippocampus at both 20 mg and 40 mg dose levels, compared to the control group. A similar trend was observed in the cortex.

What is the next step for Hoth Therapeutics (HOTH) in developing HT-ALZ?

Hoth Therapeutics plans to continue advancing HT-ALZ through further studies and clinical trials, aiming to provide a novel therapeutic option for patients suffering from Alzheimer's disease.

What is the significance of reduced reactive astrocytes in Alzheimer's treatment?

Reactive astrocytes play a role in the progression of neurodegenerative diseases like Alzheimer's. The reduction in reactive astrocytes observed with HT-ALZ treatment suggests a potential breakthrough in Alzheimer's treatment, as it corresponded with improved cognitive function.